China Moutai Showcases Ecology Promotion Practices at the China Pavilion During COP29
At a side event titled "Ecological Civilization and Beautiful China Practices" during the 2024 UN Climate Change Conference (COP29) in Baku, Azerbaijan, China Moutai showcased its commitment to ecological sustainability and called for greater attention to climate change.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113718721/en/
Li Wang, General Manager of China Moutai Group, presented at the side event in Baku. (Photo: Business Wire)
Li Wang, General Manager of China Moutai Group, emphasized that Chinese modernization is rooted in achieving harmony between humanity and nature.
She said that as a representative of China’s liquor industry, Moutai has embraced the principle that "lucid waters and lush mountains are invaluable assets." This philosophy underscores the company’s approach to modernization, which prioritizes environmental stewardship.
Wang highlighted Moutai Group’s dedication to leveraging regional ecological resources and local industrial development to promote sustainable growth. Key initiatives include supporting ecological agriculture, forestry, carbon-sink projects, and eco-tourism. The company is committed to advancing high-level protection and sustainable development of the Chishui River Basin, where Moutai is based.
To date, Moutai Group has invested over US$ 55 million in the protection of the Chishui River Basin’s ecological environment. Through its efforts, the company has developed replicable technical guidelines, operational standards, and best practices—collectively known as the "Moutai Plan"—which serve as a model for other regions seeking to balance environmental protection with economic development.
Moutai’s contributions to building a Beautiful China through practical actions and significant achievements underscore its commitment to ecological sustainability. By sharing these initiatives, Moutai aims to raise awareness of climate change and inspire broader global action.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113718721/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata HCR Redefines Automotive Timing Devices With the Total Frequency Tolerance of ±40PPM Under -40°C to +125°C Operation14.11.2024 03:00:00 CET | Press release
Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) unveils a cutting-edge electronic timing device featuring exceptional accuracy ±40ppm and reliability even in wide-temperature -40°C to +125°C conditions. By addressing the limitations of current timing components in automotive electronic systems, it enhances the design and deployment of next-generation In-Vehicle Networks (IVN), wireless communication, and Advanced Driver Assistance Systems (ADAS) functions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113670074/en/ Murata Manufacturing Co., Ltd.: The new Timing Devices, XRCGE_M_F series (Photo: Business Wire) As the automotive industry continues to pursue greater integration and electronic downsizing to address the expanding number of critical electronic systems, the performance requirements for components are growing. In order to achieve tighter packaging without compromising accuracy, it is now necessar
SBC Medical Group Holdings Inc. Reports Third Quarter 2024 Financial Results13.11.2024 22:59:00 CET | Press release
SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 HighlightsTotal revenues for the three months ended September 30, 2024 were $53 million, representing an increase of 12% from $47 million in the same quarter of 2023. Total revenues for the nine months ended September 30, 2024 was $160 million, representing an increase of 23% from $131 million in the same period of 2023. Income from operations for the three months ended September 30, 2024 was $13 million, representing a decrease by 31% from the same quarter in 2023. This result was impacted by $12.8 million of stock-based compensation expense related to the Company’s listing process. Income from operations for the nine months ended September 30, 2024 was $65.5 million, representing an increase of
Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services13.11.2024 18:00:00 CET | Press release
Altasciences, a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the diverse needs of clients. By delivering high-quality, flexible bioanalytical services, Altasciences remains dedicated to advancing drug development and empowering clients across every phase of research. For three decades now, Altasciences has taken pride in evolving their solutions to meet the needs of pharmaceutical and biotechnology companies of all sizes, including the expansion of their labs in Seattle, WA, Columbia, MO, and Laval, Québec. Their three state-of-the-art bioanalytical laboratories feature mirrored operations and uniform protocols to maintain consistency and quality across client projects, ensuring reliable, high-quality data regardless of location. This
Medidata Secures Highest Leadership Position in Everest Group’s First Life Sciences Clinical Trial Management System Products PEAK Matrix® Assessment13.11.2024 15:30:00 CET | Press release
Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, has been recognized as a leader in Everest Group's first-ever Life Sciences Clinical Trial Management System Products PEAK Matrix® Assessment 2024. The report assessed 13 providers based on the market impact of their products and their ability to deliver successful, high-quality offerings. Medidata Rave CTMS leads the industry by providing seamless, real-time patient data outputs that transform enrollment tracking and enable faster, data-driven decisions. Offering instant visibility for study teams, Rave CTMS streamlines collaboration, eliminates manual data entry, and accelerates trial timelines with exceptional accuracy. “We are honored to be recognized as the highest leader in CTMS by Everest Group,” said Tom Doyle, chief technology officer, Medidata. “This accolade underscores our unwavering commitment to transforming research and reaffirms our strategy to deliver
Appeals Court Confirms Conviction of Intercos Korea in Kolmar Korea Tech Theft13.11.2024 15:00:00 CET | Press release
Intercos Korea to be held criminally liable for leaking and misusing Kolmar Korea’s trade secrets Kolmar Korea (KRX: 161890) has won the victory in the remand trial against Intercos Korea, the Korean subsidiary of Italian cosmetics firm Intercos, concerning the misappropriation of its core sunscreen technology. The latest ruling has confirmed Intercos Korea is guilty of stealing Kolmar Korea’s technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113259255/en/ Kolmar Korea R&D Complex (photo: Kolmar Holdings) The 3-2 Criminal Division of the Suwon District Court sentenced a fine of KRW 5 million on Intercos Korea for breaching the Unfair Competition Prevention and Trade Secret Protection Act on October 18. While the court reduced the fine from an initial KRW 10 million to KRW 5 million, it upheld the conviction of Intercos Korea. The ruling became final as Intercos Korea opted not to file an appeal. Intercos Korea wa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom